CAR-37 T cell therapy (Massachusetts General Hospital)

N/A

Report date: 2022/05/16 09:05:02

Base Information

Drug NameCAR-37 T cell therapy (Massachusetts General Hospital)
Drug Alias NameCART37 (Massachusetts General Hospital)CAR-37 T细胞疗法-马萨诸塞总医院
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionLeukocyte antigen CD37 modulatorsT lymphocyte replacements
TargetsLeukocyte antigen CD37
Therapy Area/IndicationsHematologic NeoplasmsLymphoma, T-CellLymphoma, B-Cell +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMassachusetts General Hospital
China Registration ClassN/A

Develop Information

Active CompaniesMassachusetts General Hospital
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsLymphoma, T-CellLymphoma, B-Cell +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A